Learn what popular and promising peptides are, what they're being studied for, what's known, and where the evidence gets wobbly—without needing a science degree.
No sales. No protocols. No miracle claims.
Status
Approval boundaries
Evidence
Human vs early research
Unknowns
What studies miss
Quick answer
Status first. Claims second. Sources always.
Start somewhere useful
A GLP-1 medicine with FDA-approved products for type 2 diabetes and chronic weight management.
A dual GIP/GLP-1 receptor agonist approved for specific metabolic and sleep-apnea uses.
An investigational triple-receptor agonist in Phase 3 clinical trials.
An established GLP-1 medicine approved for specific diabetes and weight-management uses.
A growth hormone-releasing factor analog approved for a narrow HIV-related indication.
A growth hormone-releasing hormone analog whose former FDA-approved product was discontinued.
Related frontier molecules
NAD+, metabolites, postbiotics, and geroscience medicines often appear in the same conversations as peptides. This companion library examines them without blurring what they are, what they are approved for, or how much human evidence they have.
Cellular coenzyme
A central cellular coenzyme with legitimate biology but little clinical-outcomes evidence for wellness infusions.
mTOR-inhibiting medicine
An FDA-approved immunosuppressant with serious risks and unproven longevity use in healthy people.
Gut-microbiome-derived metabolite
A mitophagy-related metabolite with human biomarker and muscle-endurance signals but no approved disease use.
A four-question reality check
You don't need to decode every chart. Start with four sturdy questions.
Approved for this exact use, in trials, or not approved?
Human outcomes, early studies, or mostly animal and lab work?
A trustworthy summary tells you what research cannot answer yet.
Prefer FDA records, trial registries, and peer-reviewed research.
Compare carefully
Our comparison guides put approval status and evidence on the same page—without crowning a “winner.”
All comparisonsHow semaglutide, tirzepatide, liraglutide, and investigational retatrutide differ in targets, evidence, and approval status.
A status-first look at approved medicines and experimental peptides discussed for body weight.
What the evidence really says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.
Research updates
Why the 4TAZPower trial matters for Forzinity's narrow Barth syndrome approval.
FDA & regulatoryWhat the Zepbound approval covers, what supported it, and what it does not mean.
Clinical trialsWhat company-reported Phase 3 results do and do not mean while retatrutide remains investigational.
Start with the basics: what peptides are, why approval status matters, and how a promising study becomes—or doesn't become—a medicine.